시장보고서

상품코드

2076232

인터페론 베타 제제 시장 : 제품 유형별, 투여 경로별, 유통 채널별, 지역별

Interferon Beta Drugs Market, By Product Type, By Route Of Administration, By Distribution Channel, By Geography

발행일: 2026년 04월 | 리서치사: 구분자

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

가격

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,500

￦ 6,415,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 7,000

￦ 9,979,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,256,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

인터페론·베타 제제 시장은 2026년에 47억 6,000만 달러 규모에 달할 것으로 추정되고 있으며, 2033년까지 63억 5,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 4.2%로 성장할 것으로 전망되고 있습니다.

리포트 범위		리포트 상세
기준연도 :	2025년	2026년 시장 규모 :	47억 6,000만 달러
과거 데이터 기간 :	2020-2024년	예측 기간 :	2026-2033년
2026-2033년 예측 기간의 CAGR :	4.20%	2033년 시장 규모 예측 :	63억 5,000만 달러

인터페론 베타 제제는 임상적 고립 증후군, 재발-완화형 다발성 경화증(MS), 그리고 활동성 이차 진행형 다발성 경화증을 포함한 재발형 다발성 경화증(MS)의 치료에 사용됩니다. 이 약물은 질환을 완전히 치료하는 것은 아니지만, 신체 기능 장애를 유발하는 증상의 진행을 늦추고 재발 횟수를 줄이는 효과가 있습니다. 인터페론은 감염과 싸우기 위해 인체 내에서 생성되는 천연 물질입니다. 인터페론 베타 제제는 인터페론 베타-1A, 인터페론 베타-1B 및 페그인터페론 베타-1A로 분류됩니다.

시장 역학

다발성 경화증은 흔히 나타나는 신체 장애를 동반하는 신경질환으로, 주로 20세에서 50세 사이의 연령대에서 진단됩니다. 다발성 경화증 재단에 따르면 2017년 기준으로 이 자가면역 질환은 250만 명에게 영향을 미치고 있으며, 전 세계 연간 발병률은 인구 10만 명당 약 7건입니다. 또한 이 조사에 따르면 유병률은 인종이나 지역적 위도에 따라 다르며, 10만 명당 50명에서 120명 사이인 것으로 나타났습니다. 또한 다발성 경화증 재단(2015년)에 따르면 미국에서는 약 40만 명이 이 질환을 앓고 있으며, 매주 약 200건의 신규 환자가 진단되고 있습니다. Healthline Media가 2015년에 실시한 조사에 따르면 다발성 경화증은 울혈성심부전에 이어 2위를 차지했으며, 환자 1인당 연간 직접·간접 의료비는 8,528달러에서 5만 4,244달러 사이인 것으로 나타났습니다. 따라서 다발성 경화증 유병률의 증가는 전 세계 인터페론 베타 제제 시장의 성장을 이끄는 주요 요인이 되고 있습니다.

본 조사의 주요 특징 :

이 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신약 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트도 제공하고 있습니다.
이 조사에서는 다음의 매개변수를 바탕으로 전 세계 인터페론 베타 제제 시장의 주요 기업 개요을 작성하고 있습니다. 구체적으로는 기업 개요, 재무 실적, 의약품 포트폴리오, 시장내 입지, 유통 전략, 주요 발전 사항, 전략 및 향후 계획입니다.
이 보고서를 통해 얻은 인사이트는 기업의 마케팅 담당자 및 경영진이 향후 의약품 출시, 약물 분류의 업그레이드, 시장 확대 및 마케팅 전략과 관련하여 정보에 기반한 의사결정을 내릴 수 있도록 돕습니다.
이 '세계의 인터페론 베타 제제 시장' 보고서는 투자자, 공급업체, 제약사, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 전 세계 인터페론 베타 제제 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 4.76 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.20%	2033 Value Projection:	USD 6.35 Bn

Interferon beta drug is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug does not completely cure the condition, but slows down progression of some of the disabling effects and decreases the number of relapses of the disease. Interferons are natural substances produced in the human body to help fight infections. Interferon beta drugs are categorized in Interferon Beta-1A, Interferon Beta-1B, and Peginterferon Beta-1A.

Market Dynamics

Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20-50 years. According to the Multiple Sclerosis Foundation, in 2017, this autoimmune condition affects 2.5 million people with an annual global incidence of around 7 cases per 100,000 people. The study also states that prevalence rates vary between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000. Moreover, according to the Multiple Sclerosis Foundation, 2015, an estimated 400,000 people live with the disease in U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, 2015, multiple sclerosis ranks second after congestive heart failure with direct and indirect health care costs ranging from US$ 8,528 to US$ 54,244 per patient per year. Thus, increasing prevalence of multiple sclerosis is a major factor driving the growth of global interferon beta drugs market.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global interferon beta drugs market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Biogen Idec., Merck KGaA, Novartis Pharmaceuticals Corporation, and Bayer
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global interferon beta drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interferon beta drugs market.

Detailed Segmentation:

Global Interferon Beta Drugs Market, By Product Type (Revenue, USD Bn, 2021 - 2033)
Interferon Beta-1A
Interferon Beta-1B
Peginterferon Beta-1A
Global Interferon Beta Drugs Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
Intramuscular
Subcutaneous
Intravenous
Global Interferon Beta Drugs Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Interferon Beta Drugs Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- By Product Type:
  - Interferon Beta-1A
  - Interferon Beta-1B
  - Peginterferon Beta-1A
- By Route of Administration:
  - Intramuscular
  - Subcutaneous
  - Intravenous
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - U.S.
  - Canada
Latin America
- By Product Type:
  - Interferon Beta-1A
  - Interferon Beta-1B
  - Peginterferon Beta-1A
- By Route of Administration:
  - Intramuscular
  - Subcutaneous
  - Intravenous
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Product Type:
  - Interferon Beta-1A
  - Interferon Beta-1B
  - Peginterferon Beta-1A
- By Route of Administration:
  - Intramuscular
  - Subcutaneous
  - Intravenous
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Product Type:
  - Interferon Beta-1A
  - Interferon Beta-1B
  - Peginterferon Beta-1A
- By Route of Administration:
  - Intramuscular
  - Subcutaneous
  - Intravenous
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Product Type:
  - Interferon Beta-1A
  - Interferon Beta-1B
  - Peginterferon Beta-1A
- By Route of Administration:
  - Intramuscular
  - Subcutaneous
  - Intravenous
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country/Region:
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Product Type:
  - Interferon Beta-1A
  - Interferon Beta-1B
  - Peginterferon Beta-1A
- By Route of Administration:
  - Intramuscular
  - Subcutaneous
  - Intravenous
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles:
Biogen Idec
Merck KGaA
Novartis Pharmaceuticals Corporation
Bayer

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Route Of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Interferon Beta Drugs Market, By Product Type, 2021-2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Interferon Beta-1A
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
Interferon Beta-1B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
Peginterferon Beta-1A
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)

5. Global Interferon Beta Drugs Market, By Route Of Administration, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)

6. Global Interferon Beta Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)

7. Global Interferon Beta Drugs Market, By Region, 2021-2033, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2021-2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Biogen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merck KGaA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

9. Section

Research Methodology
About Us

인터페론 베타 제제 시장 : 제품 유형별, 투여 경로별, 유통 채널별, 지역별